CND Life Sciences Market Research Report
Background
Overview
CND Life Sciences, founded in 2017 by Dr. Todd D. Levine, Dr. Christopher Gibbons, and Dr. Roy Freeman, is a biotechnology company headquartered in Scottsdale, Arizona. The company specializes in developing diagnostic tools for neurodegenerative diseases, focusing on detecting key pathological markers in the peripheral nervous system through minimally invasive techniques.
Mission and Vision
CND Life Sciences is dedicated to advancing patient care by providing objective pathological insights into underlying disease processes, enabling earlier detection and improved outcomes for neurodegenerative diseases. Their vision is to help clinicians detect and treat these conditions more easily, safely, and effectively than ever before.
Industry Significance
Operating within the healthcare and biotechnology sectors, CND Life Sciences addresses the critical need for accurate and early diagnosis of neurodegenerative diseases, a growing concern due to aging populations worldwide. Their innovative diagnostic solutions contribute to the broader effort of enhancing patient care and advancing medical research in neurology.
Key Strategic Focus
Core Objectives
CND Life Sciences aims to provide clinicians with reliable, minimally invasive diagnostic tools that facilitate early detection of neurodegenerative diseases, thereby improving patient outcomes and advancing research in the field.
Areas of Specialization
The company specializes in cutaneous neurodiagnostics, focusing on detecting and quantifying misfolded alpha-synuclein proteins in skin nerve fibers, which are indicative of various synucleinopathies.
Key Technologies Utilized
- Syn-One Test®: A proprietary diagnostic test that uses immunofluorescence techniques to detect phosphorylated alpha-synuclein in cutaneous nerve fibers.
Primary Markets Targeted
CND Life Sciences primarily targets the healthcare market, collaborating with clinicians, hospitals, and research institutions to provide diagnostic solutions for patients with suspected neurodegenerative diseases.
Financials and Funding
Funding History
CND Life Sciences has raised a total of $37.51 million across 11 funding rounds. Notable investors include LabCorp, the National Institutes of Health (NIH), and the Department of Health and Human Services (HHS).
Utilization of Capital
The funds have been utilized to support the development and commercialization of the Syn-One Test®, expand laboratory operations, and advance research initiatives in neurodegenerative diagnostics.
Pipeline Development
Key Pipeline Candidates
- Syn-One Test®: The primary product, designed to detect misfolded alpha-synuclein proteins in skin nerve fibers, aiding in the diagnosis of synucleinopathies.
Stages of Development
The Syn-One Test® has completed clinical validation, demonstrating over 95% sensitivity in detecting synucleinopathies. It is currently available for clinical use.
Target Conditions
The test is intended for diagnosing various synucleinopathies, including Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, and pure autonomic failure.
Anticipated Milestones
Future milestones include expanding the test's availability, obtaining additional regulatory approvals, and conducting further research to enhance diagnostic capabilities.
Technological Platform and Innovation
Proprietary Technologies
- Syn-One Test®: Utilizes immunofluorescence techniques to detect and quantify phosphorylated alpha-synuclein in skin nerve fibers, providing an objective diagnostic tool for synucleinopathies.
Significant Scientific Methods
- Immunofluorescence: A technique employed in the Syn-One Test® to visualize and quantify specific proteins in tissue samples.
AI-Driven Capabilities
While specific AI-driven capabilities are not detailed, the company's focus on innovative diagnostic methods suggests potential integration of advanced technologies in future developments.
Leadership Team
Executive Profiles
- Richard J. Morello: Chief Executive Officer since early 2020, with over 25 years of experience in health and life sciences, including roles at Aptus Health and Plasma Surgical.
- Todd D. Levine, MD: Chief Medical Officer and Co-Founder, a clinical neurologist with over 25 years of experience, specializing in peripheral nervous system disorders.
- Christopher Gibbons, MD MMSc: Chief Scientific Officer and Co-Founder, a clinician-scientist involved in the investigation and treatment of autonomic and peripheral nerve disorders.
- David Peterson: Senior Vice President, Finance & Strategy, with 15 years of experience in healthcare, finance, and consulting, including roles at AbbVie and J.P. Morgan.
- Sowmya Arunkumar: Senior Vice President, Regulatory Affairs and Quality Assurance, bringing over 20 years of experience in diagnostics, medical devices, and digital health.
- Kevin Parker: Senior Vice President, Operations, with over 18 years of experience in life sciences, overseeing laboratory operations, supply chain, IT, and project management.
- Kathryn Van Wie: General Counsel & Senior Vice President, Commercial Strategy & Market Development, with over a decade of experience in life sciences and healthcare.
- Melanie Thistle: Senior Vice President, Commercial, with 30 years of experience in commercial strategy and leadership across biotechnology, precision medicine, and diagnostics.
